← back to search

Michael A. Weber

State University of New York · US
Area of research
Cardiology and Cardiovascular Medicine · Endocrinology, Diabetes and Metabolism
Research interest
Research interests include Blood Pressure and Hypertension Studies, Hormonal Regulation and Hypertension, Sodium Intake and Health, and Heart Rate Variability and Autonomic Control.
h-index
93
citations
45,278
works
825
NIH funding
primary concept
Medicine
email

Recent publications

Long-Term Safety and Efficacy of Renal Denervation: 24-Month Results From the SPYRAL HTN-ON MED Trial
Circulation Cardiovascular Interventions 2025cited by 9position: middledoi
Impact of Antihypertensive Medication Changes After Renal Denervation Among Different Patient Groups: SPYRAL HTN-ON MED
Hypertension 2024cited by 29position: middledoi
Endovascular Ultrasound Renal Denervation to Treat Hypertension
JAMA 2023cited by 175position: middledoi
Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications
Journal of the American College of Cardiology 2023cited by 108position: middledoi
Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials
JAMA Cardiology 2023cited by 82position: middledoi
Alcohol-mediated renal denervation in patients with hypertension in the absence of antihypertensive medications
EuroIntervention 2023cited by 52position: middledoi
Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program
Circulation 2023cited by 35position: middledoi
Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial
The Lancet 2022cited by 278position: middledoi
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial
The Lancet 2022cited by 221position: middledoi
2022 World Hypertension League, Resolve To Save Lives and International Society of Hypertension dietary sodium (salt) global call to action
Journal of Human Hypertension 2022cited by 72position: middledoi
Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial
Hypertension Research 2022cited by 51position: middledoi
Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation
JAMA Cardiology 2022cited by 45position: middledoi
Hypertension in stroke survivors and associations with national premature stroke mortality: data for 2·5 million participants from multinational screening campaigns
The Lancet Global Health 2022cited by 43position: middledoi
Hypertension urgencies in the SPYRAL HTN-OFF MED Pivotal trial
Clinical Research in Cardiology 2022cited by 10position: firstdoi
Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial
The Lancet 2021cited by 405position: middledoi
Home blood pressure monitoring: methodology, clinical relevance and practical application: a 2021 position paper by the Working Group on Blood Pressure Monitoring and Cardiovascular Variability of the European Society of Hypertension
Journal of Hypertension 2021cited by 169position: middledoi
Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation
Journal of the American College of Cardiology 2021cited by 108position: lastdoi
Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension
Journal of the American College of Cardiology 2021cited by 53position: middledoi
Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by <scp>SCAI</scp> and <scp>NKF</scp>
Catheterization and Cardiovascular Interventions 2021cited by 40position: middledoi
Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study
Journal of Human Hypertension 2021cited by 33position: middledoi
A re-examination of the SPYRAL HTN-OFF MED Pivotal trial with respect to the underlying model assumptions
Contemporary Clinical Trials Communications 2021cited by 7position: middledoi
Definition of acute kidney injury impacts prevalence and prognosis in ACS patients undergoing coronary angiography
BMC Cardiovascular Disorders 2021cited by 6position: middledoi
Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial
The Lancet 2020cited by 579position: middledoi
Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies
European Heart Journal 2020cited by 95position: middledoi
12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation
JACC: Cardiovascular Interventions 2020cited by 64position: middledoi
Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design
Clinical Research in Cardiology 2020cited by 39position: middledoi
Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial
Circulation 2019cited by 121position: middledoi
Emergence of Home Blood Pressure-Guided Management of Hypertension Based on Global Evidence
Hypertension 2019cited by 80position: middledoi
Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial
The Lancet 2018cited by 768position: middledoi
Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial
The Lancet 2018cited by 710position: middledoi

Grants

Inflation Expectations of Decision Makers and their Management
NSF2149129$646,0002022–2026PIRePORTER
Price Rigidity and The Granular Origin of Aggregate Fluctuations
NSF1756997$475,6982018–2022PIRePORTER

Frequent collaborators

Felix Mahfoud · University of Basel15 papers (2015–2025)David E. Kandzari · Santa Rosa Junior College14 papers (2015–2025)Raymond R. Townsend · Newcastle University13 papers (2013–2025)Michael Böhm · University of Stuttgart12 papers (2015–2025)Kazuomi Kario · Jichi Medical University12 papers (2015–2025)Roland E. Schmieder · Bayer (Germany)11 papers (2017–2025)George L. Bakris · University of Mississippi11 papers (2012–2021)Stuart Pocock · London School of Hygiene & Tropical Medicine11 papers (2015–2025)Martin Fahy · JenaValve (United States)10 papers (2016–2024)Konstantinos Tsioufis · Hellenic Air Force8 papers (2020–2025)William B. White · University of Connecticut6 papers (2012–2013)Sandeep Brar · Medtronic (Ireland)6 papers (2020–2025)Debbie L. Cohen · University of Pennsylvania4 papers (2013–2022)Stuart Kupfer · Brigham and Women's Hospital4 papers (2012–2013)Agustín J. Ramiréz · York University4 papers (2013–2022)Domenic Sica · Virginia Commonwealth University4 papers (2012–2013)Christian W. Hamm · German Centre for Cardiovascular Research4 papers (2012–2021)Sebastian Ewen · Saarland University4 papers (2016–2022)Antony Walton · The Alfred Hospital3 papers (2021–2024)Ernesto L. Schiffrin · Hôpital du Sacré-Cœur de Montréal3 papers (2013–2016)